Methods and compositions for diagnosis and prognosis of renal injury and renal failure
It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.
1. A method of preconditioning a subject for a therapeutic intervention comprising a cardiac or vascular surgery and testing the preconditioned subject, the method comprising:
performing a remote ischemic preconditioning procedure on the subject; and
performing a first assay and a second assay on a body fluid sample obtained from the subject after performing the remote ischemic preconditioning procedure,
wherein the first assay measures an amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in the sample and the second assay measures an amount of Tissue inhibitor of metalloproteinases 2 (TIMP2) in the sample, and
wherein the first and second assays are performed prior to performance of the therapeutic intervention for which the subject was preconditioned.
2. The method of claim 1 , wherein the therapeutic intervention comprises a heart valve repair/replacement, a percutaneous coronary intervention (PCI), a coronary artery bypass grafting, an aneurysm repair, an endovascular stent repair, or a cardiac surgery requiring cardiopulmonary bypass.
3. The method of claim 1 , wherein the therapeutic intervention further comprises administration of one or more nephrotoxic agents.
4. The method of claim 3 , wherein the one or more nephrotoxic agents comprises a radiocontrast agent, an antibiotic with nephrotoxic potential, a heavy metal preparation, a cancer chemotherapeutic agent, a nonsteroidal anti-inflammatory drug [NSAID], tacrolimus, an aminoglycoside, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, methotrexate, or streptozotocin.
5. The method of claim 1 , wherein the remote ischemic preconditioning procedure comprises applying multiple cycles of a period of ischemia induced by inflating a blood-pressure cuff applied to the subject to at least 50 mmHg followed by a period of reperfusion.
6. The method of claim 1 , further comprising combining a first assay result from the first assay and a second assay result from the second assay to provide a single composite value, wherein the single composite value is the product of multiplying the concentration of IGFBP7 and the concentration of TIMP2.
7. The method of claim 6 , further comprising performing a second remote ischemic preconditioning procedure if the single composite value is below a predetermined threshold, wherein the predetermined threshold is about 0.5 (ng/ml) 2 /1000.
8. The method of claim 7 , further comprising performing a second remote ischemic preconditioning procedure if the single composite value is below a predetermined threshold, wherein the predetermined threshold is between about 0.3 (ng/ml) 2 /1000 and about 3 (ng/ml) 2 /1000.
9. The method of claim 7 , further comprising performing a second remote ischemic preconditioning procedure if the single composite value is below a predetermined threshold, wherein the predetermined threshold is between about 0.5 (ng/ml) 2 /1000 and about 2 (ng/ml) 2 /1000.
10. The method of claim 6 , further comprising performing the therapeutic intervention.
11. A method of testing a subject after treatment with a remote ischemic preconditioning procedure, the method comprising:
performing a first assay and a second assay on a body fluid sample obtained from the subject having received the remote ischemic preconditioning procedure,
wherein the first assay measures an amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in the sample and the second assay measures an amount of Tissue inhibitor of metalloproteinases 2 (TIMP2) in the sample, and
wherein the first and second assay are performed after the remote ischemic preconditioning procedure had been performed on the subject and prior to performance of a therapeutic intervention for which the subject was preconditioned, wherein the therapeutic intervention comprises a cardiac or vascular surgery.
12. The method of claim 11 , further comprising performing the therapeutic intervention.
13. The method of claim 12 , wherein the therapeutic intervention comprises a heart valve repair/replacement, a percutaneous coronary intervention (PCI), a coronary artery bypass grafting, an aneurysm repair, an endovascular stent repair, or a cardiac surgery requiring cardiopulmonary bypass.
14. The method of claim 12 , wherein the therapeutic intervention comprises a cardiac surgery requiring cardiopulmonary bypass.
15. The method of claim 11 , wherein the therapeutic intervention further comprises administration of one or more nephrotoxic agents, wherein the one or more nephrotoxic agents comprises a radiocontrast agent, an antibiotic with nephrotoxic potential, a heavy metal preparation, a cancer chemotherapeutic agent, a nonsteroidal anti-inflammatory drug [NSAID], tacrolimus, an aminoglycoside, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, methotrexate, or streptozotocin.
16. The method of claim 11 , the method further comprising multiplying a first assay result and a second assay result to produce single composite value, wherein the first assay result is a concentration of IGFBP7 and the second assay result is a concentration of TIMP2.
17. The method of claim 16 , further comprising performing a second remote ischemic preconditioning procedure if the single composite value is below a predetermined threshold, wherein the predetermined threshold is about 0.5 (ng/ml) 2 /1000.
18. The method of claim 16 , further comprising performing a second remote ischemic preconditioning procedure if the single composite value is below a predetermined threshold, wherein the predetermined threshold is between about 0.3 (ng/ml) 2 /1000 and about 3 (ng/ml) 2 /1000.
19. The method of claim 16 , further comprising performing a second remote ischemic preconditioning procedure if the single composite value is below a predetermined threshold, wherein the predetermined threshold is between about 0.5 (ng/ml) 2 /1000 and about 2 (ng/ml) 2 /1000.
20. The method of claim 12 , further comprising performing the remote ischemic preconditioning procedure.